Copyright
        ©The Author(s) 2021.
    
    
        World J Clin Cases. Dec 6, 2021; 9(34): 10484-10493
Published online Dec 6, 2021. doi: 10.12998/wjcc.v9.i34.10484
Published online Dec 6, 2021. doi: 10.12998/wjcc.v9.i34.10484
            Table 1 The characteristics of patients with two malignancies, n (%)
        
    | Characteristics | Synchronous MPM | Metachronous MPM | Total | 
| Patients | 51 (23.0) | 171 (77.0) | 222 (100) | 
| Gender | |||
| Male | 32 (62.7) | 87 (50.9) | 119 (53.6) | 
| Female | 19 (37.3) | 84 (49.1) | 103 (46.4) | 
| Age in yr, median (range) | |||
| First cancer | 62 (32-84) | 55 (19-87) | 56 (19-87) | 
| Second cancer | 62 (32-84) | 64 (28-90) | 64 (28-90) | 
| The most common sites in first primary cancers | |||
| 1st | Esophagus, 9 (17.6) | Breast, 31 (18.1) | Breast, 33 (14.9) | 
| 2nd | Colorectum, 8 (15.7) | Colorectum, 23 (13.7) | Colorectum, 31 (14.0) | 
| 3rd | Bladder/thyroid/hypopharynx, 4 (7.8), respectively | Stomach, 14 (8.2) | Stomach, 17 (7.7) | 
| The most common sites in second primary cancers | |||
| 1st | NSCLC, 12 (23.5) | NSCLC, 54 (31.6) | NSCLC,66 (29.7) | 
| 2nd | Stomach, 9 (17.6) | Stomach, 15 (8.8) | Stomach, 24 (10.8) | 
| 3rd | Esophagus/kidney, 6 (11.8), respectively | Liver, 13 (7.6) | Esophagus/liver, 16 (7.2), respectively | 
| Median interval (range) between the first and second cancers (mo) | 0.2 (0-5.9) | 73.2 (6.3-536.8) | 43.6 (0-536.8) | 
| Metastasis | 16 (31.4) | 83 (48.5) | 99 (44.6) | 
| Median overall survival in mo | 36.4 | 35.3 | 35.4 | 
            Table 2 The most common multiple primary malignancies in patients with two malignancies
        
    | Malignancies | Total | Synchronous MPM | Metachronous MPM | Median OS in mo | 
| NSCLC and breast cancer | 12 | 2 | 10 | 79.8 | 
| NSCLC and gastric cancer | 10 | 0 | 10 | 16.7 | 
| Colorectal cancer and gastric cancer | 10 | 3 | 7 | Not reached | 
| Esophageal cancer and gastric cancer | 9 | 6 | 3 | 36.2 | 
| NSCLC and bladder cancer | 7 | 2 | 5 | 31.2 | 
| NSCLC and cervical cancer | 6 | 1 | 5 | 35.5 | 
| NSCLC and thyroid cancer | 6 | 2 | 4 | Not reached | 
| NSCLC and colorectal cancer | 6 | 1 | 5 | Not reached | 
| NSCLC and esophageal cancer | 6 | 3 | 3 | Not reached | 
            Table 3 Univariate analysis and multivariate analysis of the prognostic factors of overall survival in patients with two malignancies
        
    | Factors | Cases | Univariate analysis | Multivariate analysis | |||
| Median OS in mo | P | HR | 95%CI | P | ||
| Gender | 0.114 | |||||
| Male | 119 | 31.2 | ||||
| Female | 103 | 37.1 | ||||
| Age at second cancer (yr) | 0.038 | 1.016 | 1.000-1.032 | 0.046 | ||
| ≤ 65 | 128 | 36.4 | ||||
| > 65 | 94 | 28.4 | ||||
| Metastasis | 0.000 | 4.291 | 2.743-6.710 | 0.000 | ||
| No | 123 | 86.9 | ||||
| Yes | 99 | 20.4 | ||||
| MPM | 0.809 | |||||
| Synchronous | 51 | 36.4 | ||||
| Metachronous | 171 | 35.3 | ||||
            Table 4 The clinical features of 21 patients with three malignancies
        
    | Case | Sex | First cancer | Second cancer | Third cancer | Metastases | Outcome | OS since third cancer in mo | 
| 1 | M | Parotid cancer | Colon cancer | Penile cancer | Yes | Dead | 0.6 | 
| 2 | F | Small cell lung cancer | Colon cancer | Soft tissue sarcoma | No | Dead | 14.4 | 
| 3 | M | Gastric cancer | Liver cancer | Rectal cancer | Yes | Dead | 14.0 | 
| 4 | M | Rectal cancer | Renal cancer | Colon cancer | No | Alive | 23.1 | 
| 5 | M | Colon cancer | Bladder cancer | Renal pelvis cancer | No | Alive | 67.5 | 
| 6 | F | Soft tissue sarcoma | Colon cancer | Bladder cancer | Yes | Dead | 4.8 | 
| 7 | F | Colon cancer | Endometrial cancer | Breast cancer | Yes | Alive | 23.8 | 
| 8 | F | Breast cancer | Parotid cancer | Neuroendocrine carcinoma | Yes | Dead | 9.5 | 
| 9 | M | Bladder cancer | Thyroid cancer | Ureteral cancer | No | Alive | 18.9 | 
| 10 | M | Rectal cancer | Colon cancer | Cholangiocarcinoma | Yes | Dead | 6.0 | 
| 11 | M | Laryngeal cancer | Esophageal cancer | Non-small cell lung cancer | No | Alive | 21.5 | 
| 12 | M | Thyroid cancer | Laryngeal cancer | Rectal cancer | Yes | Dead | 10.2 | 
| 13 | M | Bladder tumor | Colon cancer | Non-small cell lung cancer | No | Dead | 12.7 | 
| 14 | M | Laryngeal cancer | Renal pelvis cancer | Bladder cancer | No | Dead | 12.9 | 
| 15 | F | Rectal cancer | Thyroid cancer | Breast cancer | Yes | Dead | 95.4 | 
| 16 | F | Skin squamous cell carcinoma | Skin basal cell carcinoma | Endometrial cancer | Yes | Alive | 57.7 | 
| 17 | F | Gallbladder cancer | Endometrial cancer | Rectal cancer | No | Alive | 15.4 | 
| 18 | F | Endometrial cancer | Rectal cancer | Pancreatic cancer | Yes | Dead | 6.0 | 
| 19 | F | Breast cancer | Thymic cancer | Choriocarcinoma | No | Alive | 18.8 | 
| 20 | F | Breast cancer | Thyroid cancer | Liver cancer | Yes | Alive | 9.0 | 
| 21 | M | Prostate cancer | Gastric cancer | Colon cancer | Yes | Dead | 7.9 | 
            Table 5 The characteristics of patients with three malignancies, n (%)
        
    | Characteristics | n (%) | 
| Total | 21 | 
| Gender | |
| Male | 11 (52.4) | 
| Female | 10 (47.6) | 
| Age in yr, median (range) | |
| First cancer | 47 (18-74) | 
| Second cancer | 54 (33-87) | 
| Third cancer | 57 (34-89) | 
| The most common cancers | |
| Colon cancer | 9 (14.3) | 
| Rectal cancer | 7 (11.1) | 
| Breast cancer | 5 (7.9) | 
| Bladder/endometrial/thyroid cancer | 4 (6.3), respectively | 
| Laryngeal cancer | 3 (4.8) | 
| Metastasis | 12 (57.1) | 
| Median OS since third cancer in mo | 14.4 | 
- Citation: Wang XK, Zhou MH. Clinical features and survival of patients with multiple primary malignancies. World J Clin Cases 2021; 9(34): 10484-10493
- URL: https://www.wjgnet.com/2307-8960/full/v9/i34/10484.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i34.10484

 
         
                         
                 
                 
                 
                 
                 
                         
                         
                        